Rough Draft Atlanta on MSN3h
Researchers expect FDA to approve a twice-yearly shot that reduces risk of HIV infection by 96%Roughly 61,000 Georgians live with HIV, the sexually transmitted virus (STI) that can lead to AIDS, and Atlanta ranks in the ...
WHO is convening a Guideline Development Group (GDG) for the development of new guidelines on the use of injectable ...
The US drug administration has approved the use of the medication as an injection for use against the multidrug resistant ...
We came across a bullish thesis on Gilead Sciences, Inc. (NASDAQ:GILD) on Substack by Magnus Ofstad. In this article, we will ...
In Donald Trump’s 2019 State of the Union Address, he made “a commitment to eliminate the HIV epidemic in the United States ...
A new drug is hugely effective at protecting people from HIV infection and needs to be injected only twice a year.
Wesley Sundquist’s lab laid foundation for development of a highly effective, long-lasting preventive measure against HIV.
Lenacapavir, approved by the US FDA, presents a groundbreaking advancement in the battle against HIV. Developed by Gilead ...
The post appears to reference the drug lenacapavir, which reportedly can cost around $40,000 annually in the U.S. and is administered in twice-yearly doses. While the drug appears to be effective ...
That's the title that Science magazine is bestowing upon the medication called lenacapavir — a twice yearly injectable that ...
This year we saw more examples of the destructive effort to undermine abortion as a health service. But overreach into health practices was not limited to abortion care.
Uganda is registering around 38,000 new infections despite the deployment of different interventions such as condoms and oral ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback